Psoriasis in Pregnancy: Study Supports Safety of Biologic Treatment – Medscape Analysis
Recent clinical data indicates that biologic therapies for psoriasis do not significantly increase the risk of adverse pregnancy outcomes, according to a study analysis. The findings suggest that these targeted treatments provide a viable option for women with severe psoriasis to maintain disease control during pregnancy without compromising fetal development or maternal health.
How Biologic Treatments Impact Psoriasis During Pregnancy
Biologic medications, which target specific proteins in the immune system to reduce inflammation, have emerged as a primary tool for managing moderate-to-severe psoriasis. For pregnant women, the decision to continue or start these therapies involves balancing the risks of the medication against the risks of uncontrolled systemic inflammation.
According to clinical research, biologics—specifically those targeting tumor necrosis factor (TNF), interleukin-17 (IL-17), and interleukin-23 (IL-23)—show a favorable safety profile. The study indicates that these drugs do not correlate with higher rates of miscarriage, congenital malformations, or preterm birth when compared to the general population. This is a significant shift from older systemic treatments, such as methotrexate, which are strictly contraindicated during pregnancy due to known teratogenic effects.
Medical professionals note that the goal of treatment is to achieve the lowest effective dose to maintain remission. Because psoriasis can either improve or worsen during pregnancy—a phenomenon known as the “psoriasis paradox”—the need for biologic intervention varies by patient. When psoriasis flares severely during gestation, it can lead to complications including systemic inflammation and increased cardiovascular stress on the mother.
The Mechanism of Action in Gestation
Biologics work by neutralizing specific cytokines. For example, TNF inhibitors block the action of TNF-alpha, a protein that triggers inflammation. Because these are large molecules, their transfer across the placenta occurs differently than small-molecule drugs. Most biologics are IgG antibodies; these typically do not cross the placenta in significant amounts during the first trimester but increase in transfer during the second and third trimesters.
This timing is critical. Since the most sensitive period for fetal organogenesis is the first trimester, the limited placental transfer of biologics during this window contributes to the low rate of congenital anomalies reported in the study.
Comparing Biologic Classes and Pregnancy Outcomes
Not all biologics function the same way, and their safety profiles differ based on the specific pathway they inhibit. The study highlights three primary classes of biologics used for psoriasis and their general impact on pregnancy.
| Biologic Class | Primary Targets | Pregnancy Safety Profile | Key Consideration |
|---|---|---|---|
| TNF Inhibitors | TNF-alpha | Well-documented; generally safe | Higher placental transfer in 3rd trimester |
| IL-17 Inhibitors | Interleukin-17A | Emerging data; shows low risk | Effective for rapid skin clearance |
| IL-23 Inhibitors | Interleukin-23 | Positive early indicators | Longer dosing intervals may be beneficial |
TNF Inhibitors: The Established Standard
TNF inhibitors, including adalimumab and infliximab, have the longest track record of use in pregnancy. Data suggests that these agents do not increase the risk of birth defects. However, because they are IgG1 antibodies, they cross the placenta more readily in the third trimester. Some clinicians suggest discontinuing TNF inhibitors after the 26th week of pregnancy to ensure the newborn is not born with suppressed TNF activity, though this remains a point of clinical debate depending on the mother’s disease severity.
IL-17 and IL-23 Inhibitors: The Newer Wave
The study also examines newer biologics like secukinumab (IL-17) and guselkumab (IL-23). While these have less historical data than TNF inhibitors, the available evidence supports their safety. IL-23 inhibitors are particularly noted for their long half-lives, which may allow for fewer injections during the pregnancy term, reducing the burden on the patient.
Why Managing Psoriasis is Critical for Maternal Health
There is a common misconception that psoriasis is merely a skin condition. In reality, it is a systemic inflammatory disease. Leaving severe psoriasis untreated during pregnancy is not a “neutral” choice; it carries its own set of clinical risks.
- Systemic Inflammation: High levels of systemic inflammation are linked to an increased risk of preeclampsia and gestational diabetes.
- Psoriatic Arthritis: For women with psoriatic arthritis, untreated joint inflammation can severely limit mobility and increase the risk of permanent joint damage during the physical strain of pregnancy.
- Psychological Impact: Severe skin flares can lead to significant psychological distress, anxiety, and depression, which are known to negatively impact pregnancy outcomes.
- Infection Risk: Severe, broken skin from psoriasis plaques can serve as an entry point for bacterial infections, potentially leading to sepsis in extreme cases.
“The decision to treat is not just about the skin; it is about reducing the overall inflammatory burden on the mother’s body to ensure the healthiest possible environment for the fetus.”
Clinical Timing and Treatment Strategies
The study emphasizes a personalized approach to timing. The strategy typically shifts depending on whether a woman is planning a pregnancy or discovers she is already pregnant.
Pre-conception Planning
For women planning to conceive, the recommendation is often to stabilize the disease using a biologic several months before pregnancy. This ensures that the patient enters the first trimester in remission, potentially allowing for a reduction in dosage or a temporary pause in treatment during the critical early stages of fetal development.
Management During the First Trimester
The first trimester is the most sensitive period for fetal development. If a patient is stable, some physicians may opt to hold the medication. However, if the disease is severe, the study suggests that the risk of uncontrolled inflammation may outweigh the minimal risk associated with biologic use, as most biologics do not cross the placenta significantly during this stage.
The Third Trimester Transition
As mentioned, the transfer of IgG antibodies increases toward the end of pregnancy. The primary concern here is not the health of the fetus in utero, but the health of the neonate after birth. A baby born to a mother on biologics may have detectable levels of the drug in their system, which could theoretically delay the response to certain neonatal infections. This is why some providers recommend a “washout” period in the final weeks of pregnancy.
For more information on medication transitions, see a related explainer on prenatal medication safety.
Common Misconceptions About Biologics and Pregnancy
Despite the evidence provided in the study, several myths persist among patients and some healthcare providers. Addressing these is essential for informed consent.
Myth 1: “Biologics suppress the entire immune system.”
Unlike broad immunosuppressants (like corticosteroids or cyclosporine), biologics are targeted therapies. They do not shut down the immune system; they block one specific pathway (e.g., IL-17). This precision is why they are generally safer for the fetus than traditional systemic immunosuppressants.
Myth 2: “It is always safer to stop all medication during pregnancy.”
The “natural” approach can be dangerous in cases of severe disease. Untreated systemic inflammation is a known risk factor for pregnancy complications. The safest path is often the one that maintains a state of low inflammation.
Myth 3: “Biologics cause birth defects.”
The study analyzed in this report found no statistically significant increase in congenital malformations. The structural development of the fetus appears unaffected by the targeted nature of these proteins.
The Role of the Multidisciplinary Care Team
Managing psoriasis in pregnancy requires a coordinated effort. The study suggests that outcomes are improved when a patient is managed by a team rather than a single provider. This team typically includes:
- Dermatologist: Manages the skin manifestations and adjusts the biologic dosage.
- Rheumatologist: Essential for patients with psoriatic arthritis to manage joint health.
- Obstetrician/Maternal-Fetal Medicine (MFM) Specialist: Monitors fetal growth and screens for pregnancy-specific complications like preeclampsia.
- Primary Care Physician: Coordinates overall health and manages comorbidities like hypertension or diabetes.
This collaborative approach allows for real-time adjustments. For instance, if an MFM specialist detects a complication, the dermatologist can quickly pivot the treatment plan to minimize risks while keeping the disease in check.
Long-term Implications for Neonatal Care
While the study supports the safety of biologics for the mother and fetus, there are specific considerations for the newborn. The most notable is the administration of live vaccines.
Because the infant may have circulating biologic antibodies (especially from TNF inhibitors) inherited from the mother, their immune response to live vaccines—such as the BCG vaccine for tuberculosis—may be delayed or diminished. Clinical guidelines generally recommend delaying live vaccines until the drug has cleared the infant’s system, which is typically several months after birth. Non-live vaccines are generally considered safe and are administered on the standard schedule.
Parents are encouraged to inform their pediatrician if biologics were used during the third trimester to ensure the vaccination schedule is optimized for the infant’s specific immune profile.
Frequently Asked Questions
Are biologics safe to start after I am already pregnant?
According to the study, biologics can be used during pregnancy if the benefits outweigh the risks. If a woman experiences a severe flare after conception, a physician may initiate biologic therapy. The decision is based on the severity of the disease and the current trimester.
Which biologic is the safest for pregnancy?
There is no single “safest” biologic, as the choice depends on the patient’s previous response to the drug. However, TNF inhibitors have the most extensive historical data supporting their safety. IL-17 and IL-23 inhibitors are also showing strong safety profiles in recent analyses.
Will my baby have psoriasis because I took biologics?
Biologics treat the symptoms and inflammation of psoriasis; they do not change the genetic predisposition to the disease. The use of biologics during pregnancy does not cause the child to develop psoriasis.
Do I need to stop my medication in the third trimester?
This depends on the specific medication and the mother’s disease stability. Some doctors recommend stopping TNF inhibitors around week 26 to reduce the amount of drug transferred to the baby. Others suggest continuing if the risk of a maternal flare is high. This must be decided in consultation with a specialist.
Can I use topical steroids instead of biologics?
Topical steroids are often the first line of defense for mild psoriasis. However, for moderate-to-severe cases, topicals are often insufficient to control systemic inflammation. Biologics are used when topical treatments fail or when the disease is too extensive for creams to be practical.
Moving Toward Personalized Pregnancy Care
The shift toward supporting biologic use during pregnancy represents a broader trend in medicine: moving away from a “one size fits all” approach to pregnancy. By recognizing that severe psoriasis is a systemic threat, clinicians can now offer a more nuanced strategy that protects both the parent and the child.
Future research is expected to focus on larger, prospective cohorts to further refine the timing of “washout” periods and the precise impact of the newest IL-23 inhibitors. For now, the data suggests that women with psoriasis do not have to choose between their own health and the health of their pregnancy; with proper medical supervision, both can be maintained.
Patients are advised to consult with their healthcare provider to create a tailored treatment plan. For those seeking more information on managing autoimmune conditions, a related guide on systemic inflammation may provide additional context.
